Volume 32, Issue 5 (August 2021)                   Studies in Medical Sciences 2021, 32(5): 365-375 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

URL: http://umj.umsu.ac.ir/article-1-5540-en.html
Assistant Professor,Molecular Genetics, Department Of Biology, Faculty of Sciences, Rasht Branch, Islamic Azad University, Rasht, Iran (Corresponding Authour) , najmehranji@gmail.com
Abstract:   (1782 Views)
Background & Aims: Gastric cancer is one of the five most common cancers in Iran, the sixth most common cancer in the world, and the second cause of cancer-related death worldwide. Failure to diagnose gastric cancer in early stages suggests the need to find potential biomarkers. This study aimed to evaluate the miR-195 expression as a potential biomarker in the plasma of gastric cancer patients in Guilan province.
Materials & Methods: In this case-control study, the Q-RT-PCR method was used to evaluate the expression level of miR-195 in the plasma of 25 patients with gastric cancer and 25 normal individuals. The relationship between the expression level of miR-195 and clinicopathologic features was evaluated using the ANOVA test. The receiver operating characteristic (ROC) and area under the curve (AUC) were used to evaluate the miR-195 as a potential biomarker to discriminate cancerous from non-cancerous states of the samples.
Results: Our analysis showed that miR-195 was significantly downregulated in gastric cancer patients compared to the normal individuals (p˂0.05). The AUC value of ROC analysis was 0.7325±0.008 (p=0.0119) with the sensitivity of 51.7% and specificity of 71.8%.
Conclusion: Downregulation of miR-195 in gastric cancer patients and ROC analysis suggested that miR-195 can be introduced as a potential biomarker in the diagnosis of gastric cancer in Guilan province.
Full-Text [PDF 842 kb]   (959 Downloads)    
Type of Study: Research | Subject: ژنتیک

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71(1):7-33. https://doi.org/10.3322/caac.21387 https://doi.org/10.3322/caac.21590 https://doi.org/10.3322/caac.21442 https://doi.org/10.3322/caac.21551 https://doi.org/10.3322/caac.21332 https://doi.org/10.3322/caac.21654 [DOI:10.3322/caac.21708] [PMID]
2. Larki P, Ahadi A, Zare A, Tarighi S, Zaheri M, Souri M, et al. Up-Regulation of miR-21, miR-25, miR-93, and miR-106b in Gastric Cancer. Iran Biomed J 2018;22(6):367-73. [DOI:10.29252/.22.6.367] [PMID] [PMCID]
3. Cooke CL, Torres J, Solnick JV. Biomarkers of Helicobacter pylori-associated gastric cancer. Gut Microbes 2013;4(6):532-40. [DOI:10.4161/gmic.25720] [PMID] [PMCID]
4. Zheng Q, Chen C, Guan H, Kang W, Yu C. Prognostic role of microRNAs in human gastrointestinal cancer: A systematic review and meta-analysis. Oncotarget 2017;8(28):46611-23. [DOI:10.18632/oncotarget.16679] [PMID] [PMCID]
5. Khakinezhad Tehrani F, Ranji N, Kouhkan F, Hosseinzadeh S. Apoptosis induction and proliferation inhibition by silibinin encapsulated in nanoparticles in MIA PaCa-2 cancer cells and deregulation of some miRNAs. Iran J Basic Med Sci 2020;23(4):469-82. [PMID] [PMCID]
6. Pakizehkar S, Ranji N, Naderi Sohi A, Sadeghizadeh M. Curcumin loaded PEG400-OA nanoparticles: A suitable system to increase apoptosis, decrease migration, and deregulate miR-125b/miR182 in MDA-MB-231 human breast cancer cells. Polymers for Advanced Technologies 2020;31(8):1793-804. [DOI:10.1002/pat.4906]
7. Hossainzadeh S, Ranji N, Naderi Sohi A, Najafi F. Silibinin encapsulation in polymersome: A promising anticancer nanoparticle for inducing apoptosis and decreasing the expression level of miR-125b/miR-182 in human breast cancer cells. J Cell Physiol 2019;234(12):22285-98. [DOI:10.1002/jcp.28795] [PMID]
8. Pakizehkar S, Ranji N, Sohi AN, Sadeghizadeh M. Polymersome-assisted delivery of curcumin: A suitable approach to decrease cancer stemness markers and regulate miRNAs expression in HT29 colorectal cancer cells. Polymers for Advanced Technologies 2020;31(1):160-77. [DOI:10.1002/pat.4759]
9. Shen YH, Xie ZB, Yue AM, Wei QD, Zhao HF, Yin HD, et al. Expression level of microRNA-195 in the serum of patients with gastric cancer and its relationship with the clinicopathological staging of the cancer. Eur Rev Med Pharmacol Sci 2016;20(7):1283-7. [Google Scholar]
10. Yu W, Liang X, Li X, Zhang Y, Sun Z, Liu Y, et al. MicroRNA-195: a review of its role in cancers. Onco Targets Ther 2018;11:7109-23. [DOI:10.2147/OTT.S183600] [PMID] [PMCID]
11. Deng H, Guo Y, Song H, Xiao B, Sun W, Liu Z, et al. MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 2013;518(2):351-9. [DOI:10.1016/j.gene.2012.12.103] [PMID]
12. Ye R, Wei B, Li S, Liu W, Liu J, Qiu L, et al. Expression of miR-195 is associated with chemotherapy sensitivity of cisplatin and clinical prognosis in gastric cancer. Oncotarget 2017; 8(57): 97260-97272. [DOI:10.18632/oncotarget.21919] [PMID] [PMCID]
13. Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, et al. Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem 2013;13(7):1002-13. [DOI:10.2174/18715206113139990078] [PMID] [PMCID]
14. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010;101(10):2087-92. [DOI:10.1111/j.1349-7006.2010.01650.x] [PMID]
15. Kalan Farmanfarma K, Mahdavifar N, Hassanipour S, Salehiniya H. Epidemiologic Study of Gastric Cancer in Iran: A Systematic Review. Clin Exp Gastroenterol 2020;13:511-42. [DOI:10.2147/CEG.S256627] [PMID] [PMCID]
16. Kim SJ, Choi CW. Common Locations of Gastric Cancer: Review of Research from the Endoscopic Submucosal Dissection Era. J Korean Med Sci 2019;34(35):e231-e. [DOI:10.3346/jkms.2019.34.e231] [PMID] [PMCID]
17. Siewert JR, Sendler A. Preoperative staging for gastric cancer [Internet]. Surgical Treatment: Evidence-Based and Problem-Oriented. Zuckschwerdt; 2001 [cited 2021 Sep 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK6869/ [Google Scholar]
18. Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, et al. Identification of suitable reference genes for qPCR analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 2012;57(4):897-904. [DOI:10.1007/s10620-011-1981-7] [PMID]
19. Zadeh MM, Motamed N, Ranji N, Majidi M, Falahi F. Silibinin-Induced Apoptosis and Downregulation of MicroRNA-21 and MicroRNA-155 in MCF-7 Human Breast Cancer Cells. J Breast Cancer 2016;19(1):45-52. [DOI:10.4048/jbc.2016.19.1.45] [PMID] [PMCID]
20. Menor M, Ching T, Zhu X, Garmire D, Garmire LX. mirMark: a site-level and UTR-level classifier for miRNA target prediction. Genome Biol 2014;15(10):500. [DOI:10.1186/s13059-014-0500-5] [PMID] [PMCID]
21. Ding M, Li J, Yu Y, Liu H, Yan Z, Wang J, et al. Integrated analysis of miRNA, gene, and pathway regulatory networks in hepatic cancer stem cells. J Transl Med 2015;13(1):259. [DOI:10.1186/s12967-015-0609-7] [PMID] [PMCID]
22. Talebi A, Mohammadnejad A, Akbari A, Pourhoseingholi MA, Doosti H, Moghimi-Dehkordi B, et al. Survival analysis in gastric cancer: a multi-center study among Iranian patients. BMC Surgery 2020;20(1):152. [DOI:10.1186/s12893-020-00816-6] [PMID] [PMCID]
23. Wang H, Peng R, Wang J, Qin Z, Xue L. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage. Clin Epigenetics 2018;10:59. [DOI:10.1186/s13148-018-0492-1] [PMID] [PMCID]
24. Zhao F-l, Dou Y-c, Wang X-f, Han D-c, Lv Z-g, Ge S-l, et al. Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer. Mol Biol Rep 2014;41(9):5913-22.25. Sohn W, Kim J, Kang SH, Yang SR, Cho JY, Cho HC, et al. Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma. Exp Mol Med 2015;47:e184. [DOI:10.1007/s11033-014-3466-1] [PMID]
25. Matsuoka T, Yashiro M. Biomarkers of gastric cancer: Current topics and future perspective. World J Gastroenterol 2018;24(26):2818-32. [DOI:10.3748/wjg.v24.i26.2818] [PMID] [PMCID]
26. Wu W-Y, Xue X-Y, Chen Z-J, Han S-L, Huang Y-P, Zhang L-F, et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. World J Gastroenterol 2011;17(31):3645-51. [DOI:10.3748/wjg.v17.i31.3645] [PMID] [PMCID]
27. Nie H, Mu J, Wang J, Li Y. miR‑195‑5p regulates multi‑drug resistance of gastric cancer cells via targeting ZNF139. Oncol Rep 2018;40(3):1370-8. [DOI:10.3892/or.2018.6524] [PMID] [PMCID]
28. Wang CQ. MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells. Eur Rev Med Pharmacol Sci 2019;23(9):3771-8. [Google Scholar]
29. Wang J, Li L, Jiang M, Li Y. MicroRNA-195 inhibits human gastric cancer by directly targeting basic fibroblast growth factor. Clin Transl Oncol2017;19(11):1320-8. [DOI:10.1007/s12094-017-1668-4] [PMID]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Studies in Medical Sciences

Designed & Developed by : Yektaweb